Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
about
Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Biological markers of invasive breast cancerTargeting triple-negative breast cancer: optimising therapeutic outcomesAdvances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized MedicineEstrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersPrognostic significance of deregulated dicer expression in breast cancerAmerican Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerTherapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors.Status of adjuvant endocrine therapy for breast cancer.High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.Designing adjuvant treatment based on biological measurements in the neoadjuvant settingHuman epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.FOXK2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BARD1.Breast cancer - one term, many entities?Targeted therapies for breast cancer.Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerExpression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomasPrognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast.The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtypeRibosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.Serum estrone concentration, estrone sulfate/estrone ratio and BMI are associated with human epidermal growth factor receptor 2 and progesterone receptor status in postmenopausal primary breast cancer patients suffering invasive ductal carcinomaPrognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.Poor-prognosis estrogen receptor- positive disease: present and future clinical solutionsAssessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC studyDoes lapatinib work against HER2-negative breast cancers?Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor.Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5.Tumor biology in estrogen receptor-positive, human epidermal growth factor receptor type 2-negative breast cancer: Mind the menopausal statusPrognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.Patterns in target-directed breast cancer research.
P2860
Q26748581-C1EA9350-1D8F-48D7-85FF-B41F8E9D4EB3Q26781177-B5937669-3F8B-419E-8104-E4F7C6DF2BB4Q26850892-E11D074E-5F5B-41C4-8520-0A0D84207755Q27001994-EB551104-829F-486B-A03A-64CEE18A108FQ27851630-E9401027-E5A2-43AD-8B6D-0796B3A7C66FQ28069856-550ACD23-4B8B-436D-AC2C-D1FA4DD1592FQ28393448-BFE2780F-EB32-4647-A8CF-F0140762FAD4Q30494798-0F97A5CF-2F30-43C6-97D7-36D5F162C566Q33648503-94AE67DE-D104-44A6-BFAD-46D986EB43EFQ33684843-E8CC2254-19E1-4508-9821-5B92375F3B99Q33688929-0D543523-0B7D-434F-8F5B-ED0C02FED35CQ33739138-77C9C188-56B2-454F-8633-C9E7B07C4DD5Q33867326-E31EA98C-91E2-433F-ADFB-825FF24E92C8Q33968076-DA73A289-7C5E-42FD-9486-42CFCB88F356Q34109691-164AEA45-3AAB-4E3F-8C11-A040AA133757Q34243127-2977B70B-2241-40F0-B7E5-192EE073A80BQ34423533-854E1B3B-904A-466C-BC9D-68875F688AB0Q35018233-A6D03D1C-EC7C-4884-A265-479B77939CF4Q35148809-F342FE5C-3302-4C75-96A0-9330BE1A366BQ35370118-04F446AD-6AAF-4A5C-A481-DB08CDAA1A6BQ35372584-EA19B3E2-FBA1-4821-807B-2495EFDD6C31Q35527355-36DE006F-7E57-4403-B6E6-1C04BEB1DF04Q35693944-11A2436E-AD15-4182-BF71-8B7DDE12A157Q35713817-D8257050-2466-4E83-BEC6-190DEA9F0947Q35820376-D0150FB8-9EBF-4827-868B-E6BA7D789206Q35823287-0BD376EA-BA80-4EA7-8376-024963F61649Q35904795-2EB713E7-D6AE-4128-85D9-B3E544D95B58Q35909220-2A546D31-1C6A-4EAB-A705-D2050F02705EQ35909626-803E5808-A980-4BB2-B2D6-0C97E6AF23A0Q35949291-8125BF4D-1D80-4C04-BC62-31B36C5E8E82Q35998425-3570F374-F754-4734-9F2C-B16E872273B2Q36223407-9A890645-5B66-4E05-A0AE-0483C0456D46Q36245537-1B6D69DA-63BE-4950-902E-5EC558C4FD63Q36245589-CFF9D016-7D94-49E9-AE38-814925ECD872Q36253050-1DCBA18F-AD26-496E-9BD9-A5D4B37DDE06Q36334705-8F218956-646D-47D5-B4A6-01872621EE29Q36350762-817BA4ED-3475-438F-AA9D-CE0FA0349050Q36363630-B32DBB6A-93C7-47AF-A7C1-8FD2FEA7C258Q36494250-26F45159-5238-4D93-B16A-365276F0D2DCQ36526547-D299D439-7E50-4968-A082-C3E125065A4C
P2860
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Relationship between quantitat ...... Alone or in Combination trial.
@en
Relationship between quantitat ...... Alone or in Combination trial.
@en-gb
Relationship between quantitat ...... Alone or in Combination trial.
@nl
type
label
Relationship between quantitat ...... Alone or in Combination trial.
@en
Relationship between quantitat ...... Alone or in Combination trial.
@en-gb
Relationship between quantitat ...... Alone or in Combination trial.
@nl
prefLabel
Relationship between quantitat ...... Alone or in Combination trial.
@en
Relationship between quantitat ...... Alone or in Combination trial.
@en-gb
Relationship between quantitat ...... Alone or in Combination trial.
@nl
P2093
P50
P356
P1476
Relationship between quantitat ...... Alone or in Combination trial.
@en
P2093
Aman Buzdar
Antonio Llombart Cussac
Chris Wale
Craig Allred
Denis Larsimont
Elizabeth Mallon
Emma Quinn
Fiona Knox
Hironobu Sasano
Hugh Bishop
P304
P356
10.1200/JCO.2007.12.9437
P407
P577
2008-01-28T00:00:00Z